Blueprint Medicines Corporation (BPMC) saw its loss widen to $16.83 million, or $0.62 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $12.64 million, or $0.47 a share.
Revenue during the quarter surged 79.80 percent to $6.16 million from $3.43 million in the previous year period.
Operating loss for the quarter was $16.88 million, compared with an operating loss of $12.48 million in the previous year period.
"During the third quarter of 2016, we made significant progress on our pipeline and were pleased to announce our newest drug discovery program for the treatment of fibrolamellar carcinoma, a rare liver cancer with a recognized genomic driver. This program highlights how quickly our science is moving to identify new and promising kinase drug targets, and our continued commitment to patients who need new treatment options," said Jeff Albers, chief executive officer of Blueprint Medicines. "We believe the breadth of our pipeline is unique for a company of our size, and we are looking forward to announcing the early stage data on our three Phase 1 clinical trials before year-end."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net